By submitting this form, you are agreeing to the Terms of Use and Privacy Policy.
Glyceryl trinitrate (GTN), often known as nitroglycerin, is a drug used to treat and prevent chest pain brought on by angina or cocaine use in recreational settings, as well as heart failure, high blood pressure, anal fissures, painful periods, and other conditions.
This includes heart attack-related chest pain. It can be applied topically, swallowed, injected into a vein, or placed under the tongue.
Low blood pressure and headache are typical adverse effects.Severe low blood pressure is possible. The safety of usage during pregnancy for the unborn child is unknown.
Due to the possibility of low blood pressure, it shouldn’t be taken with other PDE5 inhibitor family drugs like sildenafil.
The group of drugs known as nitrates includes nitroglycerin. Although its exact mechanism of action is unknown, it is thought to work by widening blood arteries.
GTN is a prodrug that needs to be denitrated before the active metabolite, nitric oxide, may be created by further reducing the nitrite anion or a similar species (NO).
Organic nitrates that go through these two processes in the body are referred to be nitrovasodilators, and denitration and reduction can happen in a number of ways.
Angina, acute myocardial infarction, severe hypertension, and acute coronary artery spasms are all conditions that are treated with nitroglycerin. The medication can be given intravenously, sublingually, or topically as a patch.
Glyceryl trinitrate may result in severe headaches, reflex tachycardia, and hypotension. These side effects call for analgesic treatment, which is painful and may have a detrimental impact on patient compliance.
When combined with erectile dysfunction medications known as sildenafil, tadalafil, and vardenafil, GTN can also result in severe hypotension, circulatory collapse, and death.
Global GLYCERYL TRINITRATE market accounted for $XX Billion in 2023 and is anticipated to reach $XX Billion by 2030, registering a CAGR of XX% from 2024 to 2030.
Since glyceryl trinitrate (GTN) undergoes quick metabolism in penile smooth muscle and endothelial cells to produce nitric oxide, which is essential for the establishment of an erection, GTN may satisfy this need.
MED2005, a topical GTN formulation being tested in clinical settings for the treatment of ED, was created using DermaSys technology.
A Phase 2(a) trial in males with ED revealed that MED2005 provided significant improvements in erectile function when compared to placebo, and pharmacokinetic studies have demonstrated that MED2005 enables rapid distribution of GTN after administration to the glans penis.
In this trial, MED2005 was well tolerated; there were only 21 instances of headache during sexual activity.
Compared to PDE 5 inhibitors, the current cornerstone of ED therapy, MED2005 is expected to be an effective treatment for ED with a quick start of action, good local tolerability, and fewer contraindications.
